Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine-124I evuzamitide - Attralus

Next Previous
Drug Profile

Iodine-124I evuzamitide - Attralus

Alternative Names: 124I-APi1832; 124I-AT-01; 124I-p5+14; 124I-p5+14 Injection; APi1832; AT-01; AUR-01; I-124 AT-01; IncAT-01; Iodine (I-124) Evuzamitide

Latest Information Update: 21 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Tennessee
  • Developer Attralus
  • Class Imaging agents; Peptide diagnostics; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transthyretin-related hereditary amyloidosis; Amyloid light-chain amyloidosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Amyloidosis

Most Recent Events

  • 12 Jan 2026 Bayer acquires Iodine-124I evuzamitide (AT 01) from Attralus
  • 21 May 2025 National Institute of Allergy and Infectious Diseases (NIAID) initiates enrolment in a phase I (Diagnosis) trial for Amyloidosis in USA (IV) (NCT06974877)
  • 18 May 2025 University of Tennessee initiates phase-II trial for Amyloidosis (Diagnosis) in USA (IV) (NCT06907849)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top